D2C7-IT

DRUG4 trials

Sponsors

Darell Bigner

Conditions

Brain Tumor, RecurrentGlioma, MalignantMalignant GliomaNewly Diagnosed MGMT Unmethylated GlioblastomaRecurrent Glioblastoma IDH Wildtype

Phase 1

D2C7 for Adult Patients With Recurrent Malignant Glioma

CompletedNCT02303678

Darell BignerBrain Tumor, Recurrent, Malignant Glioma

Start: 2015-05-05End: 2024-03-25Updated: 2026-06-26

Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

RecruitingNCT04547777

Darell BignerGlioma, Malignant

Start: 2021-07-09End: 2028-06-01Target: 90Updated: 2026-06-04

D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

RecruitingNCT05734560

Darell BignerNewly Diagnosed MGMT Unmethylated Glioblastoma

Start: 2023-09-06End: 2028-10-31Target: 50Updated: 2025-10-06

D2C7-IT + 2141-V11 Combination Post-resection in rGBM

RecruitingNCT06455605

Darell BignerRecurrent Glioblastoma IDH Wildtype

Start: 2025-03-17End: 2030-01-31Target: 46Updated: 2025-10-23

Related Papers

TIP-27. An assessment of the Tumor Monorail Device (TMD) for repeated sampling as part of a trial evaluating the combination of D2C7-IT and an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery (CED) and cervical perilymphatic injections (CPLIs) of 2141-V11 in recurrent glioblastoma (rGBM) patients

Neuro-Oncology2025-11-01

CTIM-30. INVESTIGATION OF THE COMBINATION OF D2C7-IT WITH AN FC-ENGINEERED ANTI-HUMANCD40 MONOCLONAL ANTIBODY (2141-V11) WHEN ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 COMPARED TO D2C7-IT CED MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM)

Neuro-Oncology2025-11-01

CTIM-13. D2C7-IT IN COMBINATION WITH AN FC-ENGINEERED ANTI-HUMANCD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM)

Neuro-Oncology2024-11-011 citations

Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models

Science Translational Medicine2023-02-0825 citations

A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG).

Journal of Clinical Oncology2022-06-0110 citations

Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).

Journal of Clinical Oncology2020-05-205 citations

Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma.

Journal of Clinical Oncology2017-05-202 citations

A combinatorial immunotherapy for malignant brain tumors: D2C7 immunotoxin and immune checkpoint inhibitors.

Journal of Clinical Oncology2017-03-011 citations

Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial.

2016-12-2424 citations

EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery

Receptors & Clinical Investigation2016-11-0715 citations